Quantum computing ETF surges 54% in 2026, still earlier than AI trade was in 2022

The Defiance Quantum ETF has accumulated $6 billion in assets and returned 54% year-to-date, placing the quantum computing sector roughly where artificial intelligence stood in early 2022 before its multiyear breakout.

The Defiance Quantum ETF (NYSEARCA: QTUM) returned 54.2% through June 2, 2026, nearly five times the S&P 500's 11% gain and more than double the Nasdaq-100's 21% advance over the same period. A $10,000 position in the fund on the last trading day of 2025 would have grown to about $15,420 by early June, according to fund data. The equal-weighted vehicle, which tracks the BlueStar Machine Learning and Quantum Computing Index, holds roughly 70 to 80 names and charges a 0.40% expense ratio.

"The quantum computing trade today sits roughly where AI was three years ago — the technology is leaving the lab, but the revenue base is still microscopic relative to the market cap," said Niccolo de Masi, chief executive officer of IonQ, in the company's Q1 earnings call. IonQ reported revenue of $64.67 million in the first quarter, growth of 755% year over year, and raised its full-year guidance to between $260 million and $270 million. The stock has gained 59% year-to-date, giving it a market capitalization of roughly $26.65 billion against that full-year revenue target.

The fund's equal-weight structure amplifies the contribution of pure-play quantum names. IonQ and Rigetti Computing (NASDAQ: RGTI) each receive the same allocation as larger holdings on every rebalance, meaning their triple-digit revenue growth drives disproportionate returns. Rigetti posted Q1 revenue of $4.4 million, nearly triple the $1.47 million from a year earlier, and now offers its 108-qubit Cepheus-1-108Q processor on Amazon Braket, Microsoft Azure Quantum, and qBraid with median two-qubit gate fidelity of 99.8%. The stock is up 21% year-to-date and has more than doubled over the trailing 12 months.

The other engine inside QTUM is its machine-learning and semiconductor exposure. Names such as Micron Technology, Marvell Technology, and Intel benefit from the same AI capital-expenditure wave that has lifted the broader technology sector. Goldman Sachs described the AI capex boom as "the dominant business and investment engine in the US economy" in its 2026 outlook, with growth driven by long-term transformative investments. That dual tailwind — pure-play quantum names compounding from tiny bases and AI-adjacent semis riding the hyperscaler spending cycle — explains how a thematic ETF with $6 billion in assets can outrun the Magnificent Seven.

Hardware milestones validate the thesis, but valuations remain extreme

Google's Willow processor, a 105-qubit chip, completed a computation in five minutes that would take today's fastest supercomputers 10 septillion years to calculate, using a technique called quantum echoes. IBM's Heron processor, a 156-qubit chip, is already being deployed in molecular chemistry applications, and the company plans to introduce Quantum Starling, a system capable of operating 100 million gates on 200 logical qubits, as a commercial product for finance and pharmaceutical industries.

The fundamental progress is real, but the valuation math is difficult to defend. IonQ trades at roughly 99 times trailing revenue. Rigetti carries an $8.93 billion market capitalization on $4.4 million in quarterly revenue. Both companies remain deeply unprofitable — IonQ posted an adjusted EBITDA loss of $97 million in Q1 and burned $151 million in operating cash, while Rigetti's GAAP net income of $33 million was almost entirely a $54 million non-cash swing in derivative warrant liabilities.

What investors should watch next

The forward case for QTUM hinges on three variables. First, IonQ's Q2 revenue guide of $65 million to $68 million — a clean beat would sustain the re-rating, while a miss at current multiples would break the trade. Second, hyperscaler capex commitments from Amazon, Microsoft, and Google, which determine whether the AI-adjacent bench inside the fund continues contributing. Third, fidelity benchmarks and customer announcements rather than qubit-count headlines — 99.8% gate fidelity on a commercially available system is the kind of metric that determines whether pharmaceutical companies will pay seven figures for access.

QTUM's 54% year-to-date gain has already priced in significant optimism. The gap between the fund's return and the S&P 500's 11% is unlikely to repeat from the current $168.76 level. But with AI ETFs such as the iShares US Technology ETF managing $25 billion and the Fidelity MSCI Information Technology Index ETF at $21 billion, the quantum computing thematic vehicle has room to grow if the technology delivers on its commercial promise. Investors considering a 1% to 3% portfolio allocation, as some strategists recommend, should watch the IonQ Q2 print due in late July as the next inflection point.

This article is for informational purposes only and does not constitute investment advice.